CREATE Medicines
PrivateLast Round
Series B
May 14, 2026
Total Funding Raised
$245M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
CREATE Medicines operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series B round in May 2026.
CREATE Medicines is a clinical-stage biotechnology company that develops mRNA-based in vivo cell therapies for the treatment of cancer, autoimmunity, and fibrosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CREATE Medicines Comparables
Compare CREATE Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Stylus Medicine | 86% | |
| Aera Therapeutics | 85% | |
| Alaya.bio | 84% |
For institutional investors. Book with your work email.
CREATE Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 14, 2026 | ||||
| Series A Extension | May 18, 2023 | ||||
| Series A | Jan 6, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CREATE Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Newpath Partners | Series B, Series A, Series A Extension |
| Hatteras Venture Partners | Series A, Series B, Series A Extension |
| Moore Strategic Ventures | Series A Extension |
| ARCH Venture Partners | Series A Extension, Series B |
| Alexandria Venture Investments | Series B, Series A Extension, Series A |
| Hatteras Investment Partners | Series A Extension |
| 8VC | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 29, 2026
Monthly visitors increased 92% MoM.
- Jul 27, 2026
Grew 19% QoQ, from 37 to 44 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 27, 2026
CREATE Medicines, Inc. plans to host a pre-congress industry workshop and present an oral abstract at the Asia-Pacific League of Associations for Rheumatology (APLAR) 2026 Congress from Oct 28th to Nov 1st '26 in South Korea.
- partners_withAug 28, 2026
CREATE Medicines, Inc. and Acuitas Therapeutics, Inc. form a strategic collaboration in Canada.
For institutional investors. Book with your work email.
CREATE Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CREATE Medicines's valuation, stock price, and market status.
Is CREATE Medicines a public or private company?
CREATE Medicines is a private company.
What is the current stock price of CREATE Medicines?
CREATE Medicines is a private company, so its shares have no public market price. Caplight tracks CREATE Medicines's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CREATE Medicines worth (valuation)?
Valuation information for CREATE Medicines is not publicly available.
Can I buy CREATE Medicines stock?
CREATE Medicines shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CREATE Medicines's last funding round?
CREATE Medicines's most recent funding round was Series B on May 14, 2026.
Who are the main investors in CREATE Medicines?
Key investors in CREATE Medicines include Newpath Partners, Hatteras Venture Partners, ARCH Venture Partners, Hatteras Investment Partners.
Will CREATE Medicines IPO soon?
No public IPO plans have been announced for CREATE Medicines.
How can I track CREATE Medicines secondary market activity?
Caplight tracks bids, offers, and trades in CREATE Medicines's shares on secondary markets.